Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.35 |
| ▸ | SAT1 | P21673 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.33 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177948 | 0.95 | LPAR3 (0.45) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A | |
| SCHEMBL19699811 | 0.95 | LPAR3 (0.43) | LPAR3LPAR2LPAR1PLA2G2ACYP3A4 | |
| SCHEMBL10178024 | 0.93 | LPAR3 (0.48) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A | |
| SCHEMBL15935828 | 0.93 | LPAR3 (0.48) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A | |
| SCHEMBL2523093 | 0.90 | LPAR3 (0.43) | LPAR3LPAR2LPAR1ALDH1A1CYP3A4 | |
| SCHEMBL6352756 | 0.85 | BTN3A1 (0.38) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A | |
| SCHEMBL18917021 | 0.84 | LPAR3 (0.59) | LPAR3LPAR2LPAR1PLA2G2ABTN3A1 | |
| SCHEMBL3823071 | 0.84 | CYP3A4 (0.56) | LPAR3LPAR2LPAR1PLA2G2ACYP3A4 | |
| SCHEMBL16559184 | 0.84 | LPAR3 (0.39) | LPAR3LPAR2LPAR1PLA2G2ACYP3A4 | |
| SCHEMBL13912179 | 0.82 | SAT1 (0.49) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026421-A1 | METHODS FOR CAPTURING LONG POLYNUCLEOTIDES FOR SEQUENCING SPECIFIC GENOMIC REGIONS | GENERATION BIOTECH, LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11821023-B2 | Method for capturing long polynucleotides for sequencing specific gnomic regions | GENERATION BIOTECH, LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230159934-A1 | INSULIN RECEPTOR APTAMER AND PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES COMPRISING THE SAME | Aptamer Sciences Inc. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20180164280-A1 | MODIFIED NUCLEIC ACIDS FOR NANOPORE ANALYSIS | IBIS BIOSCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180164280-A1 | MODIFIED NUCLEIC ACIDS FOR NANOPORE ANALYSIS | IBIS BIOSCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180030523-A1 | OLIGONUCLEOTIDE FRAGMENT, AND METHOD AS WELL AS APPLICATION OF SELECTIVE AMPLIFICATION OF VARIANT OF TARGET NUCLEIC ACID SEQUENCE USING THE SAME | Nuhigh Biotechnologies Co. Ltd. (CN) | 2018-02-01 | — | — | US | disclosed |
| US-20170029816-A1 | MULTIVALENT OLIGONUCLEOTIDE ASSEMBLIES | CITY OF HOPE (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029816-A1 | MULTIVALENT OLIGONUCLEOTIDE ASSEMBLIES | CITY OF HOPE (US) | 2017-02-02 | — | — | US | disclosed |
| WO-2016149020-A1 | RNA INTERFERENCE AGENTS | ARROWHEAD RESEARCH CORPORATION (US) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016149331-A2 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF FACTOR XII | ARROWHEAD RESEARCH CORPORATION (US) | 2016-09-22 | — | — | WO | disclosed |
| US-8313903-B2 | Binary DNA probe for fluorescent analysis of nucleic acids | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120201807-A1 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | IDERA PHARMACEUTICALS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120142011-A1 | Modified siNA | QIAGEN GMBH | 2012-06-07 | — | — | US | disclosed |
| US-20120040867-A1 | Microarrays of Binary Nucleic Acid Probes for Detecting Nucleic Acid Analytes | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-02-16 | — | — | US | disclosed |
| US-7851453-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | IDERA PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7812000-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends | IDERA PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100254974-A1 | Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends | IDERA PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20090176318-A1 | BINARY DNA PROBE FOR FLUORESCENT ANALYSIS OF NUCLEIC ACIDS | COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2009-07-09 | — | — | US | disclosed |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | IONIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080152662-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | IDERA PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120201807-A1 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | NT5C2, ENTPD5, NT5E | LPAR3 891/4885LPAR2 1154/4885LPAR1 1370/4885 |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | RNASEH1, NSUN3, RNASEL | LPAR3 1368/4885LPAR2 2716/4885LPAR1 2705/4885 |
| US-20120142011-A1 | Modified siNA | NSUN2, SIN3A, SNRPA1 | LPAR3 2147/4885LPAR2 2422/4885LPAR1 2588/4885 |
| US-20230159934-A1 | INSULIN RECEPTOR APTAMER AND PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES COMPRISING THE SAME | INSR, INSRR, IRS1 | LPAR3 1171/4885LPAR2 1158/4885LPAR1 779/4885 |
| US-20100254974-A1 | Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends | TLR5, TLR3, TLR9 | LPAR3 1179/4885LPAR2 1594/4885LPAR1 1788/4885 |
| US-20080152662-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | TLR5, TLR3, TLR9 | LPAR3 1179/4885LPAR2 1594/4885LPAR1 1788/4885 |
| US-20090176318-A1 | BINARY DNA PROBE FOR FLUORESCENT ANALYSIS OF NUCLEIC ACIDS | SSBP1, MDH1, SNRPE | LPAR3 3604/4885LPAR2 4338/4885LPAR1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.